In carrying out population screening under subsection (a)(1), the Director shall (1) designate and provide funding for a sufficient number of HHT Treatment Centers of Excellence to improve patient access to information, treatment, and care by HHT experts; (2) conduct surveillance through a regional population study, supplemented by sentinel health care provider or center surveillance, and administrative database analyses as useful to accurately identify (A) the prevalence of HHT; and (B) the prevalence of hemorrhagic and embolic stroke and brain abscess, resulting from HHT; (3) include HHT screening questions in the Behavioral Risk Factor Surveillance System survey conducted by the Centers for Disease Control and Prevention in order to screen a broader population and more accurately determine the prevalence of HHT; (4) disseminate data collected under paragraph (2)(B) to the Paul Coverdell National Acute Stroke Registry, to be utilized for analyses of natural history of hemorrhagic and embolic stroke in HHT, and to develop screening and arteryvein malformation treatment guidelines specific to prevention of complications from HHT; (5) develop and implement programs, targeted for physicians and health care professional groups likely to be accessed by families with HHT, to increase HHT diagnosis and treatment rates through the (A) establishment of a partnership with HHT Treatment Centers of Excellence designated under paragraph (1) through the creation of an international database of patients assessed at such HHT Treatment Centers of Excellence (including with respect to phenotype information, genotype information, transfusion dependence, and radiological findings); (B) integration of such database with the universal data collection system used by the Centers for monitoring hemophilia with the blood disorders and the Paul Coverdell National Acute Stroke Registry; and (C) inclusion of other medical providers who treat HHT patients; and (6) use existing administrative databases on nonHHT Treatment Center of Excellence patients to learn about the natural history of HHT, the efficacy of various treatment modalities, and to better inform and develop screening and treatment guidelines associated with improvement in health care outcomes, and research priorities relevant to HHT. An otolaryngologist with experience and expertise in the treatment of recurrent epistaxis in HHT patients. (4) The establishment, in collaboration with a voluntary health organization representing HHT families, of an HHT resource center within the Centers for Disease Control and Prevention to provide comprehensive education on, and disseminate information about, HHT to health professionals, patients, industry, and the public. The members of the Committee shall be appointed by the Secretary, in consultation with the Director of the National Institutes of Health, and shall consist of 12 individuals who are experts in HHT or arteriovenous malformation (AVM) as follows: (i) Four representatives of HHT Treatment Centers of Excellence designated under section 317U(c)(1). In place of the 4 members otherwise required to be appointed under paragraph (2)(A)(i), the Secretary may appoint 4 experts in vascular, molecular, or basic science to serve as members of the Committee during the period preceding designation and establishment of HHT Treatment Centers of Excellence under section 317U. (D) Publication of names. The Congress finds as follows: (1) Hereditary hemorrhagic telangiectasia (HHT) is a largely undiagnosed or misdiagnosed vascular genetic bleeding disorder that causes abnormalities of the blood vessels. A person with HHT has the tendency to form blood vessels that lack the capillaries between an artery and vein.